Hessels D - Search Results

1

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA. Leyten GH, et al. Among authors: hessels d. Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15. Eur Urol. 2014. PMID: 23201468

2

Multifocal transitional cell cancer and p53 mutation analysis.

Van Der Poel HG, Hessels D, Van Leenders GJ, Bussemakers MJ, Schalken JA, Witjes JA, Debruyne FM. Van Der Poel HG, et al. Among authors: hessels d. J Urol. 1998 Jul;160(1):124-5. doi: 10.1097/00005392-199807000-00049. J Urol. 1998. PMID: 9628622 No abstract available.

3

Comparative analysis of p53 mutations in bladder washings and histologic specimens.

Vet JA, Hessels D, Marras SA, van de Kaa CA, van der Poel HG, Michalides RJ, Debruyne FM, Schalken JA. Vet JA, et al. Among authors: hessels d. Am J Clin Pathol. 1998 Nov;110(5):647-52. doi: 10.1093/ajcp/110.5.647. Am J Clin Pathol. 1998. PMID: 9802351

4

Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer.

Vet JA, Witjes JA, Marras SA, Hessels D, van der Poel HG, Debruyne FM, Schalken JA. Vet JA, et al. Among authors: hessels d. Clin Cancer Res. 1996 Jun;2(6):1055-61. Clin Cancer Res. 1996. PMID: 9816267

5

DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.

de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. de Kok JB, et al. Among authors: hessels d. Cancer Res. 2002 May 1;62(9):2695-8. Cancer Res. 2002. PMID: 11980670

6

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. Hessels D, et al. Eur Urol. 2003 Jul;44(1):8-15; discussion 15-6. doi: 10.1016/s0302-2838(03)00201-x. Eur Urol. 2003. PMID: 12814669

7

New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.

Schalken JA, Hessels D, Verhaegh G. Schalken JA, et al. Among authors: hessels d. Urology. 2003 Nov;62(5 Suppl 1):34-43. doi: 10.1016/s0090-4295(03)00759-3. Urology. 2003. PMID: 14607216 Review.

8

Applicability of biomarkers in the early diagnosis of prostate cancer.

Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Hessels D, et al. Expert Rev Mol Diagn. 2004 Jul;4(4):513-26. doi: 10.1586/14737159.4.4.513. Expert Rev Mol Diagn. 2004. PMID: 15225099 Review.

9

Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.

van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ, Raaphorst FM. van Leenders GJ, et al. Among authors: hessels d. Eur Urol. 2007 Aug;52(2):455-63. doi: 10.1016/j.eururo.2006.11.020. Epub 2006 Nov 17. Eur Urol. 2007. PMID: 17134822

10

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.

van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA. van Gils MP, et al. Among authors: hessels d. Clin Cancer Res. 2007 Feb 1;13(3):939-43. doi: 10.1158/1078-0432.CCR-06-2679. Clin Cancer Res. 2007. PMID: 17289888

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters